18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
High Dividend Growth + High Free Cash Flow Yield Stocks = a Winning Strategy
What Analysts Are Saying About Johnson & Johnson Stock
WW Surge After GLP-1 Compounding Announcement Not Justified After Study, Barclay Says
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
Eli Lilly Widens Obesity Reach With $1.4B KeyBioscience Deal
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
Goldman Sees a 'Relief Rally' Potential for These Option Calls Ahead of Earnings
Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 5 Years
Lilly Threatens Legal Action Against Copycat Zepbound Providers: Report
KeyBioscience Announces Extension Of Strategic Collaboration With Lilly On DACRA With An Additional Collaboration Molecule And Investigation Of The DACRA Platform Within Multiple Indications
Eli Lilly Analyst Ratings
Johnson & Johnson Announces TREMFYA Demonstrates Results Across Biologic-Naïve And Biologic-Refractory Patients In Crohn's Disease And Ulcerative Colitis
Bernie Sanders And AOC Clap Back At Mark Cuban's Push for FCC Chief Shakeup: 'Anyone Goes Near Lina Khan And There Will Be An Out And Out Brawl'
AbbVie Snaps Six Days of Losses, Trades in the Green
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Merck & Co Analyst Ratings
AbbVie's Options: A Look at What the Big Money Is Thinking